Log in to save to my catalogue

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_56fa97cab04d4e0d8784ee4ba0940412

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

About this item

Full title

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2019-01, Vol.10 (1), p.259-259, Article 259

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

Subjects

Subjects and topics

More information

Scope and Contents

Contents

A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with
EGFR
-mutated lung cancer. However, some patients show intrinsic resistance and an insufficient response to osimertinib. This study showed that osimertinib stimulated AXL by inhibiting a negative feedback loop. Activated AXL was associated with EGF...

Alternative Titles

Full title

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_56fa97cab04d4e0d8784ee4ba0940412

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_56fa97cab04d4e0d8784ee4ba0940412

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-018-08074-0

How to access this item